Market Analysis - Rare Diseases 2017
Importance and Scope
There are over 7,000 classified rare diseases and 70% of them have no form of treatment, there are considerable unmet needs in this area. Regulatory benefits such as longer market exclusivity, breakthrough designations, reduced fees and tax incentives are all encouraging investment. However, the marketing process and lifecycle for a rare disease drug are very different to a mass market product and require particular skills and knowledge.
Rare Diseases-2017 will be the best platform for all the specialists and super specialists, renowned Scientists, research scholars, students who are working in this field across the globe under a single roof to exchange their knowledge related to Rare Diseases and Orphan Drugs. This international event is an effort to find an alternative for invasive imaging technique against diseases like haemophilia, cystic fibrosis, lupus, motor neurone disease, acromegaly, Fragile X syndrome, Gaucher’s disease and Gorlin’s syndrome, as well as many others.
Conferenceseries LLC welcomes all the specialists and super specialists, research scholars, industrial professionals and student delegates from biomedical and healthcare sectors to be a part of the esteemed Rare Diseases-2017. It also catalyses for information exchange and networking between researchers and business entrepreneurs of diverse backgrounds for the advancement of Technology and Research in the field of Rare Diseases. As this will be the best amalgamation of academia and research involving every aspect of empirical and conceptual thinking in exploring new dimensions in this field. It is open to all types of research methodologies both from academia and industry.
Why San Antonio?
San Antonio officially the City of San Antonio, is the seventh most populated city in the United States of America and the second most populated city in the state of Texas, with a population of 1,409,019. It was the fastest growing of the top 10 largest cities in the United States from 2000 to 2010, and the second from 1990 to 2000. The city is located in the American Southwest, the south–central part of Texas, and the southwestern corner of an urban region known as the Texas Triangle.
San Antonio hosts over 100,000 students in its 31 higher-education institutions. Publicly supported schools include the University of Texas Health Science Center at San Antonio, the University of Texas at San Antonio, Texas A&M University–San Antonio, and the Alamo Community College District. The University of Texas at San Antonio is San Antonio's largest university
· Different types of Rare Diseases
· Clinical Research and Public Awareness
· Mystery Diagnosis of Rare Diseases
· Challenges in Rare Diseases Treatment
· Rare Infectious Diseases and Immune Deficiencies
· Orphan Drugs, Development trends and strategies
· Clinical Research on Orphan Drugs
· Orphan Drugs and Ethical Issues
· Future Hereditary and Rare Diseases e-Prospects of Rare Diseases
Why to attend?
In today's economic climate your business decisions are as crucial as ever. “3rd Annual Congress on Rare Diseases and Orphan Drugs” allow you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services. 3rd Annual Congress on Rare Diseases and Orphan Drugs is organizing an outstanding Scientific Exhibition/Program and anticipates the world's leading specialists involved Rare Diseases and Orphan Drugs. Your organization will benefit with excellent exposure to the leaders in Rare Diseases and Orphan Drugs. Rare Diseases-2017 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.
Specialists and super specialists, researchers, students, industrial delegates from Academia and Research along with the industrial professionals from biomedical companies and healthcare sectors.
Statistics of Researchers, Academicians and Industrial
Major Associations Worldwide
· Canadian Organization for Rare Diseases (CORD)
· National Alliances for Rare Diseases
· Organization for Rare Diseases India (ORDI)
· The Boler-Parseghian Center for Rare & Neglected Diseases
· Cystic Fibrosis Foundation
· National Organization for Rare Diseases (NORD)
· European Union Committee of Experts on Rare Diseases
· Multiple Myeloma Research Foundation
· U.S. Food and Drug Administration
· RARE Foundation Alliance
· Birmingham children’s Hospital (NHS Foundation Trust)
· Japan Patient Association
· EURORDIS Rare Diseases Europe
· Royal Society of Medicine
· EveryLife Foundation for Rare Diseases
· Global Genes Allies in Rare Diseases
· Rare Diseases South Africa
· Short Bowel Syndrome Foundation
· Rare Diseases or Syndromes and Clinical Societies
· Rare Diseases Patient Association Funding
· Rare Disorders Society Singapore
· Guardian Hands Foundation
· IRDR Intractable & Rare Diseases Research (Europe)
Top Universities Worldwide
· Harvard University
· University of Oxford
· University of Cambridge
· Rare Genomics Institute
· GMEC, The Global Medical Excellence Cluster
· University of Zurich
· Stanford University
· Cambridge University
· Yale University
· Emory University
· Karolinska University
· John Hopkins University
· Newcastle University
· University of Pittsburgh Study
· University of Valencia
· Osaka University
· McMaster University
Hospitals Associated with Rare Diseases Research Worldwide
· The Manton Center for Orphan Disease Research (Boston, USA)
· US hospital for rare disease research (USA)
· NORD (National Organization for Rare Disorders) (USA)
· Chicago Rare Disease Foundation (Chicago, USA)
· National Institute of Health (NIH) funds research consortia to study more than 200 rare diseases (USA)
· Children’s hospital of Pittsburgh (Center for Rare Disease Therapy) (USA)
· Boston Children’s Hospital (The Manton Center for Orphan Disease Research) (Boston, USA)
· Birmingham children’s Hospital (NHS Foundation Trust) (UK)
· The Children’s Hospital of Philadelphia (USA)
Industries Associated with Rare Diseases Research Worldwide
· Novartis (Switzerland)
· Pfizer (USA)
· Roche (Switzerland)
· Onyx Pharmaceuticals
· Amicus Therapeutics
· Sarepta Therapeutics
· Sanofi (France)
· Merck & Co. (USA)
· Swedish Orphan Biovitrum AB
· AstraZeneca (UK)
· Vertex Pharmaceuticals
· NPS Pharmaceuticals
· Johnson & Johnson (USA)
· Sigma-Tau Pharmaceuticals
· European Medicines Agency
· Takeda (Japan)
· Aegerion Pharmaceuticals
· Novo Nordisk (Denmark)
· Cancer Prevention Pharmaceuticals
· PharmaMar USA
· Raptor Therapeutics
· Daiichi Sankyo (Japan)
· Araim Pharmaceuticals
· Octapharma USA
· Gilead sciences (USA)
· Millennium Pharmaceuticals
· Actavis (USA)
· Amgen (USA)
· Glaxosmithkline (UK)
· Bayer HealthCare (Germany)
Glance at Market analysis report
Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease Therapeutics Market to 2018 – Improved Understanding of Rare Diseases’ Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation”, which provides insights into the orphan disease therapeutics market until 2018. It includes the geographical distribution of Fabry, Pompe, Mucopolysaccharidosis VI, Idiopathic Thrombocytopenic Purpura, Huntington’s disease and Ovarian cancer markets across the US, the top five countries of Europe and in Japan. The report provides competitive benchmarking for the leading companies and also analyses the mergers, acquisitions and licensing agreements that shape the global markets. GBI Research’s analysis shows that the overall global orphan disease therapeutics market is expected to grow at a significant compound annual growth rate (CAGR) of 13.1% from $2.3 billion 2010 to $6 billion in 2018 in the US, the top five countries of Europe and Japan. Increasing awareness of the disease and drugs among patients and physicians, patent protection and exclusivity of Nplate and Promacta for ITP market, anticipated launch of new molecules such as ACR-16, AMR-101 and HD-02 for the treatment of HD and the approval of Avastin for the treatment of advanced ovarian cancer in Europe will drive the global orphan disease therapeutics market in the forecast period.
Annualized market data for the orphan diseases therapeutics market from 2004 to 2010, forecast forward to 2018.- Analysis of the leading therapeutic segments. These include Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI, Idiopathic Thrombocytopenic Purpura, Huntington’s disease and Ovarian Cancer.- Analysis of the orphan diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan – Market characterization of the orphan diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns – Key drivers and barriers that have a significant impact on the market – Coverage of pipeline molecules in various phases of drug development – Competitive benchmarking of leading companies. The key companies studied in this report are Genzyme Corporation, Shire Plc and Biomarin - Key M&A activities, licensing agreements that have taken place between 2010 and 2011 in the global orphan diseases therapeutics market.
The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics. The report based on EvaluatePharma® data found that the worldwide orphan drug market is set to reach $127 billion by 2018, doubling that of the overall prescription drug market.
Market Growth of Rare Diseases Research
GBI Research’s analysis shows that the overall global orphan disease therapeutics market is expected to grow at a significant compound annual growth rate (CAGR) of 13.1% from $2.3 billion 2010 to $6 billion in 2018 in the US, the top five countries of Europe and Japan.
The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics. The report based on Evaluate Pharma data found that the worldwide orphan drug market is set to reach $127 billion by 2018, doubling that of the overall prescription drug market
The global orphan drugs market reached $84.9 billion in 2009 growing from $58.7 billion in 2006 from $54.5 billion in 2005.The market is expected to grow at a compound annual growth rate (CAGR) of nearly 6% to reach $112.1 billion by 2014.The U.S. accounted for 51% of the market in 2009 and is expected to grow at a CAGR of 8.9% to reach $65.9 billion by 2014.By 2020, orphan drugs will own 19% of the total share of prescription drug sale excluding generics, reaching a whopping $176 billion in annual sales, according to Andreas Hadjivasiliou, an analyst with Evaluatepharma.
Fund Allotment to Rare diseases Research
Since 1989, NORD’s research grants have resulted in at least two FDA-approved products and the publication of numerous significant journal articles. Our more than 100 disease-specific research funds are supported primarily by patients and patient organizations. Industry support is welcome and would demonstrate commitment to the study of diseases for which there are few-if any- other sources of funding.
NORD's Research Program provides seed money grants to academic scientists for clinical studies related to the development of diagnostics or treatments of rare diseases. Requests for proposals are posted once a year in the late winter or early spring. NORD's Research Program also includes the NORD/Roscoe Brady Lysosomal Storage Diseases Fellowships.
Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases. The collaborations are made possible through awards by the National Institutes of Health — totalling about $29 million in fiscal year 2014 funding — to expand the Rare Diseases Clinical Research Network (RDCRN), which is led by NIH’s National Center for Advancing Translational Sciences (NCATS).
With the overwhelming success of the previous conference, Conferenceseries LLC
invites all the participants from all over the world to attend ‘3rd Annual Congress on Rare Diseases and Orphan Drugs’
in collaboration with Organization for Rare Diseases India(ORDI)
along with Editorial Board Members, External Scientific Association, Researchers, Academicians, and Pharmaceutical Market Leaders around the globe, scheduled on October 30-November 1, 2017 San Antonio, USA.
Rare Diseases 2017
is a global platform to discuss and learn about Rare Diseases like haemophilia, cystic fibrosis, lupus, motor neurone disease, acromegaly, Fragile X syndrome, Gaucher’s disease, Gorlin’s syndrome and idiopathic disorders, rare genetic diseases, Orphan Drugs, Alzheimer’s Disease and many more.